Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

Factor VIII

Coagulation

Antihemophilic factorFactor VIII activityFVIII

Review status

Currently under review

Pending specialist review and validation.

What it shows

Factor VIII is a blood clotting protein that helps your body form stable clots after injury. The test measures the functional activity of factor VIII in your plasma, typically using a clot-based method, to see how well the protein works rather than simply how much is present.

It is commonly ordered with other coagulation tests when there is unexplained bleeding or a prolonged clotting time. It helps diagnose and monitor hemophilia A and can also aid in assessing conditions that affect factor VIII function or level.

Why it matters

Too little factor VIII activity can lead to easy bruising or bleeding, including joint or muscle bleeds, heavy menstrual bleeding, or prolonged bleeding after procedures. Markedly low activity is characteristic of hemophilia A, while mild reductions can be seen in von Willebrand disease or after certain illnesses.

Factor VIII can also rise with inflammation, stress, pregnancy, or estrogen therapy. Persistently high factor VIII activity has been associated with an increased tendency for blood clots in veins. Your clinician may use this test to evaluate bleeding, to monitor therapy, or as part of an assessment for clotting risk.

Understanding your results

If your activity is lower than expected, your clinician may repeat the test and review how the sample was collected, then consider follow-up studies such as von Willebrand factor testing, a mixing study, or an inhibitor screen. These can help distinguish inherited hemophilia A from an acquired inhibitor or other causes of abnormal clotting tests.

If your activity is higher than expected, your clinician will consider temporary factors like recent illness, stress, pregnancy, or hormone use. Results are interpreted together with your symptoms and other labs. Depending on the overall picture, next steps may include observation, treatment planning, genetic counseling, or strategies to reduce clotting risk.

Reference ranges

0.51.5 U/mL
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact Factor VIII

  • Sample collection and handling

    Underfilled or overfilled blue-top citrate tubes, difficult draws, clotted samples, delays before centrifugation, or improper storage can falsely change factor VIII activity. Ensure the tube is filled to the mark and processed promptly.

  • Acute illness and stress

    Factor VIII is an acute phase reactant, so infection, inflammation, surgery, trauma, or vigorous exercise can raise levels temporarily. Testing when you are well gives a more stable baseline.

  • Medications and therapies

    Desmopressin and factor VIII concentrates elevate measured activity. Some agents, including emicizumab and certain anticoagulants, can interfere with clot-based assays. Tell your care team about all medicines and infusions.

  • Hormones and pregnancy

    Estrogen-containing contraceptives or hormone therapy and pregnancy can increase factor VIII activity. Your clinician may interpret results in that context or time testing accordingly.

  • Blood group and age

    People with blood group O often have lower baseline von Willebrand factor, which can be accompanied by lower factor VIII activity. Levels can also rise gradually with age.

  • Recent transfusions

    Plasma transfusion or factor replacement before testing may transiently normalize or elevate activity and mask an underlying deficiency. Let the laboratory know about recent blood products.

2026

References

  1. McGill University Health Centre. (2016, March 17). Factor VIII (Task CD 18461583). Laboratory reference ranges.
  2. Srivastava, A., Santagostino, E., Dougall, A., Kitchen, S., Sutherland, M., Pipe, S. W., Carcao, M., Mahlangu, J., Ragni, M., Windyga, J., Lobet, S., Walker, I., & WFH Guidelines Development Group. (2020). WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia, 26(S6), 1-158. External link
  3. Mayo Clinic Laboratories. (2024). Coagulation Factor VIII activity, plasma. External link
  4. Lippi, G., & Favaloro, E. J. (2018). Preanalytical and analytical variables in coagulation testing. Seminars in Thrombosis and Hemostasis, 44(7), 712-729. External link